Bevacizumab, an immunoglobulin G monoclonal antibody against humanized vascular growth factor A, selectively binds to vascular endothelial factor subtype A (VEGF-A), hinders the binding of vascular endothelial growth factor to receptor tyrosine kinases (VEGFR), and initiates signaling to inhibit tumor angiogenesis (158, 159). Here, NTRK1 is linked to neoplasm.